Sorafenib
Core Binding Factor Acute Myeloid Leukemia
Explore 8 assets in Core Binding Factor Acute Myeloid Leukemia →Floatz Rating
CCC53/100
Confidence
Indicative
Sponsor
Nanfang Hospital, Southern Medical University
Modality
Small molecule
Development Phase
Phase 2
Status
Dormant
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
38Indicative
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT05404516CT.gov Combination of Sorafenib With Standard Therapy in Newly Diagnosed Adult CBF AML | — | Unknown | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
81High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Core Binding Factor Acute Myeloid Leukemia
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Sorafenib (this asset) | Nanfang Hospital, Southern Medical University | P2 | CCC · 53 |
| Daunomycin | National Cancer Institute (NCI) | P2 | B |
| Cytarabine | National Cancer Institute (NCI) | P2 | B |
| Dasatinib | National Cancer Institute (NCI) | P2 | B |
| Azacitidine | Children's Hospital of Soochow University | P2 | CCC |
| Gemtuzumab Ozogamicin | National Cancer Institute (NCI) | P2 | CCC |
| Avapritinib | Children's Hospital of Soochow University | P2 | CCC |
| Idarubicin | Children's Hospital of Soochow University | P2 | CCC |
| Decitabine | Children's Hospital of Soochow University | P2 | CCC |
+2 more in the Core Binding Factor Acute Myeloid Leukemia cohort
Other indications for Sorafenib
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Renal Cell Carcinoma | — | P4 | BBB · 79 |
| Portal Vein Thrombosis | — | P4 | BBB · 74 |
| Adult Hepatocellular Carcinoma | — | P3 | BBB · 73 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Sorafenib in Core Binding Factor Acute Myeloid Leukemia. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/sorafenib-core-binding-factor-acute-myeloid-leukemia
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →